FDA Approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
November 2024
in “
Clinical Research
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The FDA approval of deuruxolitinib, an oral JAK inhibitor, offers a promising new treatment for severe alopecia areata (AA), an autoimmune condition causing non-scarring hair loss. This approval is based on two phase 3 trials, THRIVE-AA1 and THRIVE-AA2, involving 1,220 patients, which showed significant hair regrowth compared to placebo. At 24 weeks, 29.6% of participants on an 8 mg dose and 41.5% on a 12 mg dose achieved a SALT score of ≤20. Deuruxolitinib demonstrated a manageable side effect profile, primarily headaches and acne, without significant cardiovascular risks, making it a safer alternative to other JAK inhibitors. Further research is needed to assess long-term safety and effects post-treatment.
